§ Federal grant opportunity · RFA-DK-27-147
Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)
National Institutes of Health is accepting applications for Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed). The deadline is September 30, 2026 and the published award range is $2.2M.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- September 30, 2026
- Award range
- $2.2M
- Eligibility
- Only the PI/PDs associated with the award issued under RFA-DK-20-509 to Beckman Research Institute/City of Hope is eligible to apply for this single source funding. Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- RFA-DK-27-147
Program overview
This is a NOFO for a Single Source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is announcing its intent to issue a single source cooperative agreement award to Beckman Research Institute/City of Hope for the currently funded Integrated Islet Distribution Program (IIDP) to renew the program and maintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research. The IIDP facilitates the distribution of human islets to biomedical researchers by establishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapies for the prevention and treatment of diabetes.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before September 30, 2026, allowing time for registration and validation.
Related grant opportunities
- Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed)
- NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research
- DoW Breast Cancer, Breakthrough Award Level 4
- DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
- DoW Breast Cancer, Transformative Breast Cancer Consortium Award
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.